Study of efficacy evaluation and influence factors of Chinese medical treatment for patients with neocrown pneumonia based on real world
Phase 1
- Conditions
- ovel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2100005222
- Lead Sponsor
- The First Affiliated Hospital of He'nan University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Meet the definition of confirmed patients and asymptomatic infections with delta variant new coronary pneumonia;
2. Aged 18-80 years;
3. The clinical classification of confirmed cases is light, common, severe, and critical;
Exclusion Criteria
1. Not using syndrome differentiation therapy or syndrome differentiation therapy for less than 3 days;
2. Dementia, various mentally ill patients;
3. Pregnant and lactating patients;
4. Those who are participating in clinical trials of other drugs and are known to be allergic to therapeutic drugs.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ucleic acid conversion time and rate of conversion;
- Secondary Outcome Measures
Name Time Method Depression Self-Rating Scale (SDS) scores;All cause rehospitalization rate;Prognosis;Incidence of complications;Pneumonia patient-reported outcome scale (CAP-PRO) score;Chest imaging;Clinical symptomes;Anxiety Self-Assessment Scale (SAS) scores;Post traumatic stress disorder checklist score;